In this context, depending on the type of tumor and the experimental model, the blockade of M-CSF signaling has in most cases attenuated cancer progression, a finding with potentially high clinical relevance for the use of the M-CSF receptor inhibitors as cancer therapeutics (22). The gene discussed is CSF1; the disease is neoplasm.